MedTrace Logo

Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer

NCT01317433 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-03-25

No results posted yet for this study

Summary

The aim of this study is to test the role of cycline in the prevention of acne-like skin rash in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.

Conditions

  • Colorectal Cancer Metastatic
  • Skin Toxicity

Interventions

DRUG

Doxycycline

Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.

DRUG

Cetuximab

500 mg/m² IV infusion of 60 minutes every 15 days

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Olivier Capitain, MD, PhD · Institut Cancerologie de l'Ouest

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-29
Primary Completion
2016-10-10
Completion
2016-10-10

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317433 on ClinicalTrials.gov